drugset / Trial / NCT00278369
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Combinations of biological substances in denileukin diftitox may be able to carry tumor-killing substances directly to kidney cancer cells. Interleukin-2 may stimulate the white blood cells to kill kidney cancer cells. Giving denileukin diftitox together with interleukin-2 may kill more tumor cells. PURPOSE: This randomized phase I trial is studying the side effects of denileukin diftitox and interleukin-2 in treating patients with metastatic kidney cancer.
Timeline
- Start
- 2005-04
- Primary completion
- 2009-06
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Intravenous |
| Subject | denileukin diftitox | Protein / enzyme biologic | 6 ug/kg | Intravenous |
| Subject | denileukin diftitox | Protein / enzyme biologic | 9 ug/kg | Intravenous |